WeightWatchers and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care
WeightWatchers (WGHTQ) has announced an expanded collaboration with Novo Nordisk to enhance access to FDA-approved Wegovy® (semaglutide) through WeightWatchers Clinic. The partnership includes a significant pricing initiative, offering eligible cash-pay members access to Wegovy® at a reduced price of $299 in July 2025, representing a $200 savings.
The collaboration features integration with NovoCare® Pharmacy and CenterWell Pharmacy® for prescription fulfillment and home delivery. WeightWatchers will enhance member experience through integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking.
The partnership demonstrates impressive clinical outcomes, with a study of 3,260 WeightWatchers Clinic members prescribed a GLP-1 showing an average 21% body weight loss at 12 months. Wegovy®, which supports nearly 1.5 million U.S. patients, received expanded FDA approval in 2024 for reducing major cardiovascular events in adults with known heart disease and obesity or overweight.
WeightWatchers (WGHTQ) ha annunciato un ampliamento della collaborazione con Novo Nordisk per migliorare l'accesso a Wegovy® (semaglutide) approvato dalla FDA tramite la WeightWatchers Clinic. La partnership prevede un'importante iniziativa di prezzo, offrendo ai membri idonei che pagano in contanti l'accesso a Wegovy® a un prezzo ridotto di 299$ a luglio 2025, con un risparmio di 200$.
La collaborazione include l'integrazione con NovoCare® Pharmacy e CenterWell Pharmacy® per la gestione delle prescrizioni e la consegna a domicilio. WeightWatchers migliorerà l'esperienza dei membri attraverso accesso integrato agli account, opportunità di prezzi combinati, visibilità dell'inventario e tracciamento delle spedizioni.
La partnership mostra risultati clinici impressionanti, con uno studio su 3.260 membri della WeightWatchers Clinic a cui è stato prescritto un GLP-1 che ha evidenziato una perdita media del 21% del peso corporeo in 12 mesi. Wegovy®, che supporta quasi 1,5 milioni di pazienti negli Stati Uniti, ha ottenuto nel 2024 una nuova approvazione FDA per la riduzione degli eventi cardiovascolari maggiori negli adulti con malattia cardiaca nota e obesità o sovrappeso.
WeightWatchers (WGHTQ) ha anunciado una colaboración ampliada con Novo Nordisk para mejorar el acceso a Wegovy® (semaglutida) aprobado por la FDA a través de WeightWatchers Clinic. La asociación incluye una iniciativa significativa de precios, ofreciendo a los miembros elegibles que pagan en efectivo acceso a Wegovy® a un precio reducido de $299 en julio de 2025, lo que representa un ahorro de $200.
La colaboración integra NovoCare® Pharmacy y CenterWell Pharmacy® para la dispensación de recetas y entrega a domicilio. WeightWatchers mejorará la experiencia de los miembros mediante acceso integrado a cuentas, oportunidades de precios combinados, visibilidad de inventario y seguimiento de envíos.
La asociación muestra resultados clínicos impresionantes, con un estudio de 3,260 miembros de WeightWatchers Clinic a quienes se les prescribió un GLP-1 que mostró una pérdida promedio del 21% del peso corporal en 12 meses. Wegovy®, que apoya a casi 1.5 millones de pacientes en EE.UU., recibió una aprobación ampliada de la FDA en 2024 para reducir eventos cardiovasculares mayores en adultos con enfermedad cardíaca conocida y obesidad o sobrepeso.
WeightWatchers (WGHTQ)가 Novo Nordisk와의 협력을 확대하여 FDA 승인 Wegovy® (세마글루타이드)에 대한 접근성을 WeightWatchers 클리닉을 통해 강화한다고 발표했습니다. 이번 파트너십에는 현금 결제 자격이 있는 회원들에게 2025년 7월에 $299라는 할인된 가격으로 Wegovy®를 제공하는 중요한 가격 정책이 포함되어 있으며, 이는 $200의 절감 효과를 의미합니다.
이 협력은 처방 조제 및 가정 배송을 위한 NovoCare® Pharmacy와 CenterWell Pharmacy®와의 통합을 특징으로 합니다. WeightWatchers는 통합 계정 접근, 묶음 가격 기회, 재고 가시성 및 배송 추적을 통해 회원 경험을 향상시킬 예정입니다.
이 파트너십은 GLP-1 처방을 받은 3,260명의 WeightWatchers 클리닉 회원을 대상으로 한 연구에서 12개월 동안 평균 체중 21% 감소라는 인상적인 임상 결과를 보여줍니다. Wegovy®는 거의 150만 명의 미국 환자를 지원하며, 2024년에는 심장 질환과 비만 또는 과체중이 있는 성인의 주요 심혈관 사건 감소를 위한 FDA 확장 승인을 받았습니다.
WeightWatchers (WGHTQ) a annoncé une collaboration élargie avec Novo Nordisk pour faciliter l'accès à Wegovy® (sémaglutide) approuvé par la FDA via WeightWatchers Clinic. Ce partenariat inclut une initiative tarifaire importante, offrant aux membres payant en espèces éligibles un accès à Wegovy® à un prix réduit de 299 $ en juillet 2025, soit une économie de 200 $.
La collaboration comprend l'intégration avec NovoCare® Pharmacy et CenterWell Pharmacy® pour la délivrance des prescriptions et la livraison à domicile. WeightWatchers améliorera l'expérience des membres grâce à un accès intégré aux comptes, des opportunités de tarification groupée, une visibilité des stocks et un suivi des expéditions.
Le partenariat démontre des résultats cliniques impressionnants, avec une étude menée auprès de 3 260 membres de WeightWatchers Clinic ayant reçu une prescription de GLP-1, montrant une perte moyenne de 21 % du poids corporel en 12 mois. Wegovy®, qui soutient près de 1,5 million de patients aux États-Unis, a reçu une approbation élargie de la FDA en 2024 pour réduire les événements cardiovasculaires majeurs chez les adultes atteints de maladies cardiaques connues et d'obésité ou de surpoids.
WeightWatchers (WGHTQ) hat eine erweiterte Zusammenarbeit mit Novo Nordisk angekündigt, um den Zugang zu FDA-zugelassenem Wegovy® (Semaglutid) über die WeightWatchers Clinic zu verbessern. Die Partnerschaft beinhaltet eine bedeutende Preisinitiative, die berechtigten Barzahlern den Zugang zu Wegovy® zu einem reduzierten Preis von 299 $ im Juli 2025 ermöglicht, was eine Ersparnis von 200 $ darstellt.
Die Zusammenarbeit umfasst die Integration mit NovoCare® Pharmacy und CenterWell Pharmacy® für die Rezeptabwicklung und Hauszustellung. WeightWatchers wird das Mitgliedserlebnis durch integrierten Kontozugang, gebündelte Preisoptionen, Bestandsübersicht und Sendungsverfolgung verbessern.
Die Partnerschaft zeigt beeindruckende klinische Ergebnisse, mit einer Studie von 3.260 WeightWatchers Clinic-Mitgliedern, die ein GLP-1 verschrieben bekamen und einen durchschnittlichen 21%igen Gewichtsverlust nach 12 Monaten aufwiesen. Wegovy®, das fast 1,5 Millionen US-Patienten unterstützt, erhielt 2024 eine erweiterte FDA-Zulassung zur Reduzierung schwerwiegender kardiovaskulärer Ereignisse bei Erwachsenen mit bekannter Herzkrankheit und Übergewicht oder Adipositas.
- None.
- Reduced pricing offer is limited to July 2025 only
- Pricing offer restricted to eligible cash-pay members only
WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for
Collaboration Builds a Seamless NovoCare® Pharmacy Integration, Shared Vision to Enhance Outcomes Through WW’s GLP-1 Companion Support, and a Commitment to Publishing Real-World Evidence
WeightWatchers Sets the Standard in Evidence-Based Weight Health, Prescribing Only FDA-Approved Medications
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through WeightWatchers Clinic. As the only holistic platform focused on long-term weight health featuring the No. 1 doctor-recommended weight loss program included in the recently announced collaboration with Novo Nordisk, WeightWatchers continues to reinforce its role as the trusted leader in sustainable, science-backed weight care, and one of the few in the industry to publicly commit to prescribing only FDA-approved medications.
As part of the collaboration, WeightWatchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, a seven-time MMIT Specialty Pharmacy Patient Choice Award winner for best-in-class customer satisfaction and commitment to patient care, serves as the dispensing pharmacy for the NovoCare® program and will facilitate direct fulfillment and home delivery of Wegovy® prescriptions for WeightWatchers Clinic members. In addition, WeightWatchers will enhance the member experience by providing integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking.
Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy® at a reduced price of
“By deepening our collaboration with Novo Nordisk, we are helping more people access the FDA-approved treatment they deserve, delivered within a holistic clinical model proven to support real, sustainable and improved health outcomes,” said Scott Honken, Chief Commercial Officer at WeightWatchers. “In a market increasingly cluttered with hype and shortcuts, WeightWatchers remains the trusted leader, bringing together access to safe, FDA-approved medication and best-in-class lifestyle support, setting the bar for the gold standard of responsible weight management. We are thrilled to announce this expanded collaboration with Novo Nordisk to further access, patient safety, and quality in service of our millions of members.”
In addition to affordability and access improvements, WeightWatchers and Novo Nordisk will explore opportunities to further collaborate on real-world research initiatives and strategies to improve long-term outcomes. The intent will be to evaluate the potential impact of pairing Wegovy®, the most widely used GLP-1 medication in the world, with WeightWatchers’ best-in-class nutrition and behavioral support program, to demonstrate the clinical and economic value of an integrated care model.
“As we work to expand access to life-changing, FDA-approved treatments like Wegovy®, it is essential that we partner with organizations that share our values and focus on improving long-term outcomes,” said Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc. “In a space crowded with quick-fix promises, and unapproved and unsafe compounded medications, we are excited to collaborate with WeightWatchers and their science-backed, responsible approach to care. Their focus on behavioral support, real-world outcomes, and FDA-approved treatment aligns with our values. We believe this expanded collaboration will help more people access safe, effective, and sustainable weight management.”
First approved in 2021, Wegovy® is the only FDA-approved semaglutide treatment for weight loss, and the medicine that changed how healthcare professionals treat patients with obesity as the first weekly GLP-1 for chronic weight management. Wegovy® currently supports nearly 1.5 million patients in the U.S. The FDA expanded the label in 2024 to include an indication for the reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. Wegovy® and the semaglutide molecule continue to be studied across a variety of chronic conditions.
At the heart of this expanded collaboration is a shared commitment to clinical integrity, science-backed care, and improved patient outcomes. Through WeightWatchers’ holistic weight health model, which pairs medication access with a clinically proven nutrition-based program, lifestyle change, and community support, members receive care that can improve and extend adherence and minimize side effects of weight management medications, ultimately driving more sustainable and superior results. In a study of 3,260 WeightWatchers Clinic members prescribed a GLP-1, participants lost on average
About WeightWatchers
WeightWatchers is the global leader in science-backed weight management, providing an accessible, holistic model of care through our #1 U.S. doctor-recommended Points® Program, clinical interventions including weight-loss medications (U.S. only), and community support. Since 1963, we have empowered our millions of members to build healthy habits to live longer lives. Our innovative, trusted spectrum of solutions provides members with the tools and resources they need to reach and sustain their goals wherever they are on their journey. To learn more visit weightwatchers.com or corporate.ww.com.
For media inquiries, please contact: Marielena Santana media@ww.com For investor inquiries, please contact: John Mills or Anna Kate Heller WeightWatchers@icrinc.com
FAQ
What is the new price for Wegovy® through WeightWatchers Clinic in July 2025?
What results did WeightWatchers Clinic members achieve with GLP-1 medications?
How many patients currently use Wegovy® in the United States?
What new FDA approval did Wegovy® receive in 2024?
How will WeightWatchers enhance the prescription process for Wegovy®?
